文献速递细菌感染、耐药与抗菌药物

大肠埃希菌低表达blaKPC致基因型药敏试验陷阱

Pitfalls in genotypic antimicrobial susceptibility testing caused by low expression of blaKPC in Escherichia coli.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

研究调查一例患者血培养中多株KPC阳性大肠埃希菌表型与基因型美罗培南敏感性不一致的现象。5株中3株对美罗培南敏感(MICVITEK2 ≤ 0.25 mg/L)、2株耐药(MICVITEK2 ≥ 16 mg/L),高MIC株blaKPC-2表达显著更高。结论提示基因型AMR预测对blaKPC存在局限,目前仍需补充分析以指导精准抗菌治疗。

要点

  • KPC阳性不等于美罗培南耐药,低表达株可表现为敏感
  • 基因型药敏预测blaKPC耐药存在假阳性风险
  • 当前基因型AMR预测需结合表型或其他分析辅助决策

核心结论

  • KPC阳性大肠埃希菌可因blaKPC-2低表达而表现为美罗培南敏感,基因型AMR预测对blaKPC存在局限,目前仍需额外分析以支持准确抗生素治疗决策。

研究设计与样本

  • 对单例患者血培养中分离的多株KPC阳性大肠埃希菌进行比较分析,采用WGS分析遗传特征及blaKPC-2位点,qPCR测定blaKPC-2表达,半定量碳青霉烯灭活法评估美罗培南水解能力,并用蜡螟感染实验评估临床相关性。

主要发现

  • 5株分离株均携带blaKPC-2,其中3株对美罗培南敏感(MICVITEK2 ≤ 0.25 mg/L),2株耐药(MICVITEK2 ≥ 16 mg/L)。
  • 高MIC株的blaKPC-2表达显著更高,与表型美罗培南灭活相对应。
  • 所有分离株blaKPC-2的遗传环境相同。
  • 蜡螟感染实验提示美罗培南可降低低表达KPC-Ec感染后的死亡率。

临床怎么用

  • 对KPC阳性大肠埃希菌不应仅凭基因型判定美罗培南耐药,需结合表型药敏结果综合判断。
  • 基因型AMR预测结果需谨慎解读,必要时补充表达或水解活性分析以指导用药。

局限性

  • 研究基于单例患者血培养分离株,样本量有限,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a growing interest in the rapid genotypic identification of antimicrobial resistance (AMR). In routine diagnostics, we detected multiple KPC-positive Escherichia coli (KPC-Ec) with discordant phenotypic meropenem susceptibility from a single patient's blood cultures, which prompted a more thorough investigation. OBJECTIVES: We investigated the potential clinical relevance of, and the mechanism behind, discordant phenotypic and genotypic meropenem susceptibility in KPC-Ec. METHODS: WGS was used to perform a comparative analysis of the isolates' genetic characteristics and their blaKPC-2 locus. Expression of blaKPC-2 was determined by quantitative PCR and the potency of meropenem hydrolysis was determined using a semi-quantitative carbapenem inactivation method. An in vivo infection assay using Galleria mellonella was performed to assess the potential clinical relevance of KPC expression in E. coli. RESULTS: Despite the presence of blaKPC-2, three of five isolates were susceptible to meropenem (MICVITEK2 ≤ 0.25 mg/L), while two isolates were resistant (MICVITEK2 ≥ 16 mg/L). The isolates with high MICs had significantly higher blaKPC-2 expression, which corresponds to phenotypic meropenem inactivation. The genetic environment of blaKPC-2, which may impact KPC production, was identical in all isolates. In vivo infection assay with G. mellonella suggested that meropenem was effective in reducing mortality following infection with low-expressing KPC-Ec. CONCLUSIONS: Our findings clearly highlight a limitation of genotypic AMR prediction for blaKPC. For the time being, genotypic AMR prediction requires additional analysis for accurate antibiotic therapy decision-making.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Kocer K, Klein S, Hildebrand D, et al. Pitfalls in genotypic antimicrobial susceptibility testing caused by low expression of blaKPC in Escherichia coli. J Antimicrob Chemother. 2021. PMID: 34324652. doi:10.1093/jac/dkab267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。